Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 126 | 6.980 |
Why?
|
| Sarcoma | 15 | 2023 | 142 | 2.460 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 53 | 1.700 |
Why?
|
| Bone Substitutes | 8 | 2017 | 9 | 1.540 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 16 | 1.540 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 7 | 1.380 |
Why?
|
| Bone Transplantation | 7 | 2017 | 154 | 1.210 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 8 | 1.050 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 34 | 0.910 |
Why?
|
| Humans | 60 | 2023 | 23152 | 0.890 |
Why?
|
| Limb Salvage | 5 | 2023 | 12 | 0.870 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3036 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 193 | 0.790 |
Why?
|
| Hip Joint | 2 | 2016 | 387 | 0.730 |
Why?
|
| Adult | 23 | 2022 | 7038 | 0.690 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 22 | 0.690 |
Why?
|
| Osteosarcoma | 8 | 2021 | 40 | 0.670 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 17 | 0.660 |
Why?
|
| Adolescent | 15 | 2021 | 1897 | 0.640 |
Why?
|
| Young Adult | 12 | 2021 | 1713 | 0.640 |
Why?
|
| Child, Preschool | 9 | 2021 | 563 | 0.620 |
Why?
|
| Fractures, Bone | 2 | 2012 | 70 | 0.620 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 5 | 0.610 |
Why?
|
| Tibia | 2 | 2010 | 192 | 0.600 |
Why?
|
| Child | 12 | 2021 | 1136 | 0.580 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3038 | 0.580 |
Why?
|
| Middle Aged | 21 | 2021 | 7997 | 0.550 |
Why?
|
| Male | 25 | 2021 | 12524 | 0.540 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 559 | 0.540 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.520 |
Why?
|
| Bone Diseases | 2 | 2017 | 20 | 0.510 |
Why?
|
| Arthrodesis | 2 | 2014 | 33 | 0.510 |
Why?
|
| Internal Fixators | 1 | 2016 | 34 | 0.510 |
Why?
|
| Acetabulum | 3 | 2016 | 190 | 0.500 |
Why?
|
| Foreign Bodies | 1 | 2016 | 20 | 0.500 |
Why?
|
| Foot | 1 | 2016 | 42 | 0.500 |
Why?
|
| Radiotherapy | 1 | 2016 | 31 | 0.490 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 27 | 0.490 |
Why?
|
| Female | 22 | 2021 | 13031 | 0.490 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 63 | 0.480 |
Why?
|
| Radius | 2 | 2014 | 33 | 0.460 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 203 | 0.440 |
Why?
|
| Tobramycin | 2 | 2005 | 8 | 0.430 |
Why?
|
| Survival Rate | 5 | 2021 | 307 | 0.420 |
Why?
|
| Biopsy | 6 | 2023 | 192 | 0.400 |
Why?
|
| Arthralgia | 2 | 2011 | 103 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 366 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 32 | 0.380 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 41 | 0.370 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 293 | 0.370 |
Why?
|
| Prognosis | 8 | 2023 | 722 | 0.370 |
Why?
|
| Allografts | 4 | 2021 | 140 | 0.370 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1457 | 0.360 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 4 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 56 | 0.350 |
Why?
|
| Talus | 1 | 2011 | 13 | 0.350 |
Why?
|
| Edema | 1 | 2011 | 23 | 0.350 |
Why?
|
| Patellar Ligament | 1 | 2010 | 33 | 0.340 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 421 | 0.330 |
Why?
|
| Humerus | 3 | 2005 | 90 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 543 | 0.320 |
Why?
|
| Femur | 4 | 2022 | 309 | 0.310 |
Why?
|
| Osteomyelitis | 3 | 2005 | 18 | 0.300 |
Why?
|
| Reoperation | 6 | 2022 | 764 | 0.290 |
Why?
|
| Aged | 12 | 2021 | 7448 | 0.290 |
Why?
|
| Bone Plates | 1 | 2008 | 41 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 62 | 0.270 |
Why?
|
| Cisplatin | 3 | 2017 | 60 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 699 | 0.260 |
Why?
|
| Osteogenesis | 1 | 2007 | 101 | 0.260 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 3711 | 0.250 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 237 | 0.240 |
Why?
|
| Curettage | 3 | 2022 | 9 | 0.230 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 160 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 177 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 65 | 0.230 |
Why?
|
| Knee Joint | 2 | 2008 | 574 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 335 | 0.230 |
Why?
|
| Infant | 3 | 2021 | 480 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 320 | 0.220 |
Why?
|
| Margins of Excision | 2 | 2022 | 29 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2004 | 17 | 0.210 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 86 | 0.210 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 35 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 600 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 53 | 0.200 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 128 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 70 | 0.200 |
Why?
|
| Neutrophils | 1 | 2023 | 93 | 0.200 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 355 | 0.190 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.190 |
Why?
|
| Absorbable Implants | 1 | 2002 | 18 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 535 | 0.190 |
Why?
|
| Apoptosis | 5 | 2022 | 197 | 0.190 |
Why?
|
| Bone Cements | 3 | 2022 | 79 | 0.190 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.190 |
Why?
|
| Vancomycin | 1 | 2002 | 52 | 0.190 |
Why?
|
| Radiography | 5 | 2015 | 555 | 0.190 |
Why?
|
| Debridement | 2 | 2012 | 74 | 0.180 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 8 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 83 | 0.170 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 443 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 8 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 177 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 21 | 0.160 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 248 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 10 | 0.150 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 16 | 0.150 |
Why?
|
| Dogs | 4 | 2007 | 146 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 194 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 57 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2019 | 42 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 283 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 82 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 74 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 102 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 85 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 5 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 53 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 232 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 61 | 0.130 |
Why?
|
| Piperazines | 1 | 2017 | 82 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1445 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 274 | 0.120 |
Why?
|
| Synovectomy | 1 | 2016 | 6 | 0.120 |
Why?
|
| Chondroma | 3 | 2012 | 6 | 0.120 |
Why?
|
| Child Development | 1 | 2016 | 68 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1265 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 393 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 96 | 0.120 |
Why?
|
| Risk Factors | 2 | 2022 | 1944 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 25 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 17 | 0.110 |
Why?
|
| Arthroplasty | 1 | 2016 | 114 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 94 | 0.110 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 33 | 0.110 |
Why?
|
| Lung | 1 | 2015 | 150 | 0.110 |
Why?
|
| Hand Strength | 1 | 2014 | 49 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2014 | 56 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 901 | 0.110 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 11 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 427 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 10 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2012 | 249 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 114 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 18 | 0.100 |
Why?
|
| Bone Cysts | 1 | 2012 | 1 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 28 | 0.100 |
Why?
|
| Animals | 5 | 2007 | 3253 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 58 | 0.090 |
Why?
|
| Bone Regeneration | 2 | 2003 | 69 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 318 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 600 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 30 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 35 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 20 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 22 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 27 | 0.080 |
Why?
|
| Age Factors | 2 | 2019 | 635 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 259 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 419 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 809 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 234 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1507 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 12 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 26 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 216 | 0.070 |
Why?
|
| Injections | 1 | 2007 | 41 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 80 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 23 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 5 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2006 | 42 | 0.060 |
Why?
|
| Proteins | 1 | 2006 | 53 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 97 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2006 | 88 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 14 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 128 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 319 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 284 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 90 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2011 | 735 | 0.050 |
Why?
|
| Blastomycosis | 1 | 2004 | 22 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 35 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 101 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 48 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 1 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 327 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 53 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 17 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 50 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 112 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 76 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 23 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 398 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 9 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 26 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 2 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 79 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 6 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 14 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 29 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 525 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 34 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 47 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 73 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 70 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 37 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 52 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 26 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 387 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 172 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 534 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 111 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 127 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 12 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 12 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 41 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 55 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 69 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 38 | 0.030 |
Why?
|
| Pyrazines | 1 | 2017 | 11 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 160 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 7 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 41 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 36 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 76 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 19 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 38 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 118 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 47 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 4 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 48 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 11 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 90 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 98 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 5 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 103 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 99 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 223 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 25 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 200 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 6 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 7 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 51 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 102 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 279 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 514 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 6 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 6 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 7 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 11 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 15 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 51 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 24 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 111 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 48 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 48 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 470 | 0.010 |
Why?
|